Remote Monitoring of CGM Data in Pediatric Patients With Newly Diagnosed Type 1 Diabetes (T1D)

The Use of Continuous Glucose Monitor Technology and Remote Monitoring to Change Clinical Outcomes Following New Diagnosis of Type 1 Diabetes in the Pediatric Population

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03968055

Enrollment

100

Registered

2019-05-30

Start date

2019-03-25

Completion date

2028-12-30

Last updated

2026-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

pediatrics

Brief summary

To determine if increased targeted contact between patients and the care team can improve diabetes outcomes in the 1st year after diagnosis. We will be using the GluVue platform to remotely view continuous glucose monitor (CGM) data.

Detailed description

Based on alerts from GluVue, care team members will proactively reach out to patients and their families for more frequent dose adjustments. We will assess if remote monitoring facilitates contact between the care team and patients and improves glycemic control.

Interventions

OTHERIntegration with Epic

Participants will have CGM data connected to our medical record through an already established pathway (Dexcom app on iOS device to Apple HealthKit to Epic MyChart to Epic)

Study design

Allocation

Intervention model

SEQUENTIAL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Months to 21 Years

Healthy volunteers

Inclusion criteria

* All individuals within one month of T1D diagnosis seen at the Stanford Children's Diabetes Clinic * Individuals who plan to receive follow up care at the Stanford Children's Diabetes Clinic * Individuals who agree to CGM data integration into the electronic medical record (EMR) for remote monitoring * Age: birth to \< 21 years of age

Exclusion criteria

* Diabetes diagnosis other than T1D * Diagnosis of diabetes \> 1 month prior to initial visit * Individuals with the intention of obtaining diabetes care at another clinic * Individuals who do not consent to CGM use, CGM data integration, or remote monitoring * Individuals \> 21 years of age

Design outcomes

Primary

Measure	Time frame	Description
Contacts with the care provider	1 year	Prospective chart review to determine the number of contacts between the participant and care team due to remote monitoring

Secondary

Measure	Time frame	Description
Hemoglobin A1c	1 year	Prospective chart review for lab values

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORPriya Prahalad, MD, PhD

Stanford University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 9, 2026